Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 37,354,009 shares of the biopharmaceutical company's stock after selling 231,114 shares during the period. Vanguard Group Inc. owned approximately 6.34% of Royalty Pharma worth $952,901,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Brooklyn Investment Group lifted its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 876 shares during the period. Allworth Financial LP raised its stake in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares during the last quarter. Riverview Trust Co lifted its holdings in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares during the period. Fifth Third Bancorp grew its position in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 376 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have recently weighed in on RPRX shares. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $41.60.

Royalty Pharma Price Performance

Shares of RPRX traded down $0.24 during trading hours on Monday, reaching $31.13. 7,631,854 shares of the company traded hands, compared to its average volume of 3,121,245. The stock has a market capitalization of $17.94 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The stock has a fifty day simple moving average of $32.44 and a 200 day simple moving average of $28.86. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a $0.22 dividend. The ex-dividend date was Friday, February 21st. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.83%. Royalty Pharma's dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.